Back to News
Market Impact: 0.3
InnoCare Pharma Secures NMPA Clearance For ICP-B381 Clinical Trial
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
InnoCare Pharma received Chinese NMPA Center for Drug Evaluation approval for its IND application for ICP-B381, enabling the company to begin clinical trials. The regulatory clearance advances the drug candidate into clinical development and is a positive pipeline catalyst, though no efficacy, commercial, or financial details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Pharvaris at Wells Fargo conference: oral HAE drug gains ground
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights
- Justice Department probes Nvidia’s Groq deal over antitrust concerns
- RNC Day 1 Kicks off in Dallas